Understanding the Frontline Landscape of Metastatic Triple-Negative Breast Cancer

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman introduce the evolving frontline treatment landscape for metastatic triple-negative breast cancer (mTNBC), emphasizing the aggressive nature of the disease and the ongoing unmet need for more effective treatment strategies. NP Zafman reviews the biologic characteristics that distinguish mTNBC from other breast cancer subtypes and discusses why many patients experience rapid disease progression, underscoring the importance of optimizing first-line therapy. The faculty highlights that a substantial proportion of patients may not receive second-line treatment because of clinical deterioration, reinforcing the need to maximize the benefit of initial therapy. Throughout the discussion, they set the stage for the program by outlining the expanding role of oncology nurse practitioners in treatment selection, toxicity monitoring, patient education, and multidisciplinary care coordination, while introducing the practical, case-based approach that will be used to explore evidence-based management strategies for patients with metastatic triple-negative breast cancer.